Home LiteratureArticle Details
PMID: 9811721 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.

Journal of virology ·Vol. 72 ·No. 12 ·1998-12-00 ·Pages 9855-64

Spenlehauer C, Saragosti S, Fleury HJ, Kirn A, Aubertin AM, Moog C

Abstract

Previous studies characterized the third variable (V3) loop of the envelope gp120 as the principal neutralizing determinant for laboratory T-cell-line-adapted (TCLA) strains of human immunodeficiency virus type 1 (HIV-1). However, primary viruses isolated from infected individuals are more refractory to neutralization than TCLA strains, suggesting that qualitatively different neutralizing antibodies may be involved. In this study, we investigated whether the V3 loop constitutes a linear target epitope for antibodies neutralizing primary isolates. By using peptides representative of the V3 regions of various primary isolates, an early, relatively specific and persistent antibody response was detected in sera from HIV-infected patients. To assess the relationship between these antibodies and neutralization, the same peptides were used in competition and depletion experiments. Addition of homologous V3 peptides led to a competitive inhibition in the neutralization of the TCLA strain HIVMN/MT-4 but had no effect on the neutralization of the autologous primary isolate. Similarly, the removal of antibodies that bind to linear V3 epitopes resulted in a loss of HIVMN/MT-4 neutralization, whereas no decrease in the autologous neutralization was measured. The different roles of V3-specific antibodies according to the virus considered were thereby brought to light. This confirmed the involvement of V3 antibodies in the neutralization of a TCLA strain but emphasized a more pronounced contribution of either conformational epitopes or epitopes outside the V3 loop as targets for antibodies neutralizing primary HIV-1 isolates. This result underlines the need to focus on new vaccinal immunogens with epitopes able to induce broadly reactive and efficient antibodies that neutralize a wide range of primary HIV-1 isolates.

MeSH Terms
Adaptation, Physiological Amino Acid Sequence Antibody Specificity Base Sequence Binding, Competitive Cell Line DNA Primers/genetics Epitopes/genetics HIV Antibodies HIV Antigens/genetics HIV Envelope Protein gp120/genetics,immunology HIV Infections/immunology,virology HIV-1/genetics,immunology,isolation & purification Humans In Vitro Techniques Molecular Sequence Data Neutralization Tests Peptide Fragments/genetics,immunology T-Lymphocytes/virology
Chemicals
DNA Primers Epitopes HIV Antibodies HIV Antigens HIV Envelope Protein gp120 HIV envelope protein gp120 (305-321) Peptide Fragments
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Spenlehauer C
INSERM U74, Institut de Virologie, 67000 Strasbourg, France.
Saragosti S
Fleury H J
Kirn A
Aubertin A M
Moog C
References (73)
73 references, click to expand
  1. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
    J Virol. 1994 Sep;68(9):6006-13 PMID: 8057475
  2. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.
    AIDS Res Hum Retroviruses. 1994 Jun;10(6):631-2 PMID: 8074926
  3. Neutralization of HIV-1.
    AIDS Res Hum Retroviruses. 1994 Jun;10(6):633-43 PMID: 8074927
  4. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.
    J Virol. 1994 Nov;68(11):6994-7000 PMID: 7933081
  5. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Virology. 1994 Nov 1;204(2):609-15 PMID: 7941328
  6. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    J Virol. 1994 Dec;68(12):8312-20 PMID: 7525987
  7. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Science. 1994 Nov 11;266(5187):1024-7 PMID: 7973652
  8. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    J Virol. 1995 Jan;69(1):101-9 PMID: 7527081
  9. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.
    J Virol. 1995 Jan;69(1):122-30 PMID: 7527082
  10. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
    J Infect Dis. 1997 Oct;176(4):924-32 PMID: 9333150
  11. Inhibition of HIV-1 infection by the beta-chemokine MDC.
    Science. 1997 Oct 24;278(5338):695-8 PMID: 9381181
  12. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.
    Nat Med. 1997 Nov;3(11):1250-7 PMID: 9359700
  13. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.
    J Virol. 1997 Dec;71(12):9198-205 PMID: 9371578
  14. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
    J Gen Virol. 1998 Jan;79 ( Pt 1):77-82 PMID: 9460926
  15. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
    J Virol. 1998 Mar;72(3):1876-85 PMID: 9499039
  16. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.
    J Virol. 1998 Mar;72(3):1886-93 PMID: 9499040
  17. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
    J Virol. 1998 Mar;72(3):2491-5 PMID: 9499111
  18. Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS.
    Immunol Lett. 1996 Jun;51(1-2):23-8 PMID: 8811340
  19. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  20. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.
    J Virol Methods. 1988 Aug;20(4):309-21 PMID: 2460479
  21. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  22. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
    Science. 1990 Dec 14;250(4987):1590-3 PMID: 1703322
  23. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.
    Virology. 1991 Apr;181(2):481-9 PMID: 2014634
  24. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
    Science. 1991 Jul 5;253(5015):71-4 PMID: 1905842
  25. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.
    N Engl J Med. 1995 Jan 26;332(4):201-8 PMID: 7808485
  26. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  27. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors.
    J Virol. 1995 Sep;69(9):5838-42 PMID: 7637030
  28. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    J Immunol. 1995 Oct 15;155(8):4100-10 PMID: 7561123
  29. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    J Virol. 1995 Nov;69(11):6609-17 PMID: 7474069
  30. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.
    AIDS. 1995 Aug;9(8):867-74 PMID: 7576320
  31. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.
    Nat Med. 1995 Jan;1(1):59-64 PMID: 7584954
  32. Neutralizing antibodies in slowly progressing HIV-1 infection.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 1;10(4):400-7 PMID: 7583435
  33. HIV suppression by interleukin-16.
    Nature. 1995 Dec 7;378(6557):563 PMID: 8524386
  34. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
    J Virol. 1996 Jan;70(1):427-44 PMID: 8523556
  35. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.
    J Virol. 1996 Jan;70(1):445-58 PMID: 8523557
  36. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.
    Science. 1995 Dec 15;270(5243):1811-5 PMID: 8525373
  37. Toward an understanding of the correlates of protective immunity to HIV infection.
    Science. 1996 Jan 19;271(5247):324-8 PMID: 8553066
  38. Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection.
    AIDS Res Hum Retroviruses. 1995 Oct;11(10):1153-62 PMID: 8573370
  39. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
    AIDS Res Hum Retroviruses. 1995 Nov;11(11):1379-91 PMID: 8573396
  40. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    J Infect Dis. 1996 Feb;173(2):340-8 PMID: 8568294
  41. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 15;11(5):438-47 PMID: 8605588
  42. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.
    J Virol. 1996 Jun;70(6):3668-77 PMID: 8648701
  43. Likely HIV cofactor found.
    Science. 1996 May 10;272(5263):809-10 PMID: 8629006
  44. Chemokine receptors and HIV-1: an attractive pair?
    Cell. 1996 Jul 12;86(1):1-3 PMID: 8689676
  45. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.
    AIDS Res Hum Retroviruses. 1996 May 1;12(7):585-92 PMID: 8743084
  46. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.
    J Virol. 1996 Sep;70(9):6136-42 PMID: 8709238
  47. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
    AIDS. 1995;9 Suppl A:S117-36 PMID: 8819579
  48. Early phases of HIV type 1 infection.
    AIDS Res Hum Retroviruses. 1996 Jan 1;12(1):1-9 PMID: 8825612
  49. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.
    J Gen Virol. 1996 Oct;77 ( Pt 10):2403-14 PMID: 8887471
  50. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.
    J Virol. 1996 Nov;70(11):7827-32 PMID: 8892904
  51. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):184-7 PMID: 8906796
  52. Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro.
    AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):19-27 "[| PMID: 8989423
  53. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    J Virol. 1997 May;71(5):3734-41 PMID: 9094648
  54. Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses.
    J Virol. 1997 Jun;71(6):4284-95 PMID: 9151816
  55. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
    J Immunol. 1997 Jul 1;159(1):279-89 PMID: 9200464
  56. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry.
    Virology. 1997 Sep 1;235(2):179-90 PMID: 9281497
  57. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
    Science. 1991 Oct 4;254(5028):105-8 PMID: 1718036
  58. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.
    Nature. 1992 Feb 20;355(6362):728-30 PMID: 1741059
  59. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.
    Virology. 1992 Apr;187(2):423-32 PMID: 1546447
  60. CD8+ cell anti-HIV activity: nonlytic suppression of virus replication.
    AIDS Res Hum Retroviruses. 1992 Jun;8(6):1039-50 PMID: 1354466
  61. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9434-8 PMID: 1409653
  62. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    J Virol. 1993 Feb;67(2):863-75 PMID: 7678308
  63. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    J Infect Dis. 1993 Jul;168(1):207-10 PMID: 8515110
  64. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  65. Diversity of the V3 region of HIV in Paris, France.
    AIDS. 1993 Sep;7(9):1199-204 PMID: 8216976
  66. Jitters jeopardize AIDS vaccine trials.
    Science. 1993 Nov 12;262(5136):980-1 PMID: 8235635
  67. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    J Virol. 1994 Jan;68(1):469-84 PMID: 7504741
  68. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11518-22 PMID: 7505441
  69. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.
    J Virol. 1994 Jun;68(6):3908-16 PMID: 8189527
  70. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  71. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.
    AIDS Res Hum Retroviruses. 1994 Mar;10(3):245-51 PMID: 8018385
  72. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):5142-55 PMID: 8035514
  73. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
    J Virol. 1994 Aug;68(8):5264-9 PMID: 8035523
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1998-12-00
Pages
9855-64
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC110497
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com